Novo Nordisk As Stock Cash And Equivalents
| NOVA Stock | EUR 76.20 4.40 5.46% |
Novo Nordisk AS fundamentals help investors to digest information that contributes to Novo Nordisk's financial success or failures. It also enables traders to predict the movement of Novo Stock. The fundamental analysis module provides a way to measure Novo Nordisk's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novo Nordisk stock.
Novo |
Novo Nordisk AS Company Cash And Equivalents Analysis
Novo Nordisk's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Novo Nordisk Cash And Equivalents | 1.64 B |
Most of Novo Nordisk's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novo Nordisk AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Novo Nordisk AS has 1.64 B in Cash And Equivalents. This is 99.79% higher than that of the Healthcare sector and 266.79% higher than that of the Biotechnology industry. The cash and equivalents for all Germany stocks is 39.31% higher than that of the company.
Novo Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novo Nordisk's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novo Nordisk could also be used in its relative valuation, which is a method of valuing Novo Nordisk by comparing valuation metrics of similar companies.Novo Nordisk is regarded fourth in cash and equivalents category among its peers.
Novo Fundamentals
| Return On Equity | 0.72 | |||
| Return On Asset | 0.22 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.43 % | |||
| Current Valuation | 282.15 B | |||
| Shares Outstanding | 2.25 B | |||
| Shares Owned By Insiders | 0.01 % | |||
| Shares Owned By Institutions | 8.34 % | |||
| Price To Earning | 17.63 X | |||
| Price To Book | 27.50 X | |||
| Price To Sales | 1.68 X | |||
| Revenue | 176.95 B | |||
| Gross Profit | 148.51 B | |||
| EBITDA | 76.8 B | |||
| Net Income | 55.52 B | |||
| Cash And Equivalents | 1.64 B | |||
| Cash Per Share | 0.67 X | |||
| Total Debt | 20.77 B | |||
| Debt To Equity | 9.10 % | |||
| Current Ratio | 0.96 X | |||
| Book Value Per Share | 37.10 X | |||
| Cash Flow From Operations | 78.89 B | |||
| Earnings Per Share | 3.32 X | |||
| Price To Earnings To Growth | 2.00 X | |||
| Target Price | 116.88 | |||
| Number Of Employees | 54.39 K | |||
| Beta | 0.33 | |||
| Market Capitalization | 303.37 B | |||
| Total Asset | 241.26 B | |||
| Z Score | 8.4 | |||
| Annual Yield | 0.01 % | |||
| Five Year Return | 2.26 % | |||
| Net Asset | 241.26 B | |||
| Last Dividend Paid | 12.4 |
About Novo Nordisk Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novo Nordisk AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novo Nordisk using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novo Nordisk AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Additional Information and Resources on Investing in Novo Stock
When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.